Aphios Corporation

Company Profile

Biopharmaceutical company developing enabling technology platforms and enhanced natural therapeutics for certain infectious diseases, cancers and CNS disorders
Enhanced therapeutics include small molecules from medicinal plants and marine organisms, and improved drug delivery formulations of protein macromolecules and hydrophobic anticancer drugs
Enabling technology platforms, nanotechnologies and therapeutic products covered by 33 issued U.S. and international patents, and 27 pending patent applications
History of collaborations with multinational companies such as Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly and the Gillette Company, and leading academic institutions
Research and development supported by several competitive, peer-reviewed grants from the National Institutes of Health, National Science Foundation, and National Institute of Standards and Technology, Department of Commerce

Product Pipeline

Oncology and CNS disorders therapeutic products being developed: include Zindol™ in Phase II/III clinical trials for nausea in cancer patients undergoing chemotherapy, a pre-IND lead product for Alzheimer's disease, nontoxic alkylating derivatives of Vitamin D for prostate and other cancers, and orally-bioavailable Taxotere® prodrugs with and without MAbs for improved and targeted anticancer therapies
Anti-infective therapeutic products being developed include antivirals against influenza, HIV and smallpox, and antimicrobials against gingivitis and MDR bacteria such as MRSA and VRE

Business Strategy

Hybrid business model of enabling technology platforms and enhanced therapeutic products
Baseball strategy of 'singles' from nutraceuticals, 'doubles and triples' from oncology and CNS products and 'homeruns' from anti-infectives
Spin-off or licensing of enhanced therapeutic products and enabling technology platforms for drug delivery and pathogenic safety

Management and Directors